Type 2 diabetes mellitus (T2DM) has increasingly been identified as a risk factor for sensorineural hearing loss, whereas the association between different antidiabetic therapies and hearing thresholds remains poorly characterized. This retrospective observational study evaluated 240 patients with T2DM and 105 normoglycemic controls who underwent standardized pure-tone audiometry at the Audiology Section of the...
✦ The floor
Discussion
Signed responses from readers of the wire.
Results may inform medication selection discussions for diabetic patients with hearing loss, but the retrospective design limits causal conclusions — no immediate practice change is warranted pending prospective replication.
Diabetes is a well-known risk factor for hearing loss, and understanding whether specific antidiabetic drugs protect or harm hearing could meaningfully influence prescribing and co-management between audiologists and endocrinologists.
- 01Retrospective design examining antidiabetic drug classes and audiometric thresholds in T2D patients with sensorineural hearing loss.
- 02Published in Pharmacology Research & Perspectives (doi: 10.1002/prp2.70316).
- 03Explores potential ototoxic or otoprotective effects of antidiabetic pharmacotherapy.
- 04Findings are associational only — causation cannot be established from this design.
- 05Clinically relevant given the high comorbidity rate of T2D and hearing impairment.
Different antidiabetic drug therapies are associated with differences in hearing thresholds in adults with type 2 diabetes and sensorineural hearing loss.
studypartially supported- PMID
- 42717744
- DOI
- 10.1002/prp2.70316.
- Journal
- Pharmacology Research & Perspectives
- Publication type
- research_article
- Evidence level
- 3
- Population
- Adults with type 2 diabetes and sensorineural hearing loss
- Intervention
- Various antidiabetic pharmacotherapy regimens
- Comparator
- Different antidiabetic drug classes compared against each other
Primary outcomes
Hearing thresholds (audiometric measures)